Amgen Inc. $AMGN Shares Sold by ProVise Management Group LLC

ProVise Management Group LLC reduced its stake in Amgen Inc. (NASDAQ:AMGN – Free Report) by 8.1% in the 3rd quarter, HoldingsChannel.com reports. The firm owned 15,152 shares of the medical research company’s stock after selling 1,344 shares during the period. ProVise Management Group LLC’s holdings in Amgen were worth $6,387,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Moors & Cabot Inc. lifted its stake in Amgen by 23.5% during the 3rd quarter. Moors & Cabot Inc. now owns 18,382 shares of the medical research company’s stock valued at $7,748,000 after acquiring an additional 3,498 shares during the period. Compass Capital Management Inc. boosted its position in Amgen by 27.1% in the 3rd quarter. Compass Capital Management Inc. now owns 2,345 shares of the medical research company’s stock worth $988,000 after purchasing an additional 500 shares in the last quarter. Valmark Advisers Inc. grew its position in Amgen by 7.8% during the third quarter. Valmark Advisers Inc. now owns 9,204 shares of the medical research company’s stock valued at $3,880,000 after buying an additional 669 shares during the period. Allworth Financial LP grew its position in shares of Amgen by 2.9% during the 3rd quarter. Allworth Financial LP now owns 55,440 shares of the medical research company’s stock valued at $23,369,000 after acquiring an additional 1,582 shares during the period. Finally, GKV Capital Management Co. Inc. grew its holdings in Amgen by 2.2% in the third quarter. GKV Capital Management Co. Inc. now owns 13,423 shares of the medical research company’s stock valued at $5,658,000 after purchasing an additional 295 shares during the period. Hedge funds and other institutional investors own 76.50% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research firms recently issued reports on AMGN. TD Cowen lifted their price target on shares of Amgen from $452.00 to $531.00 and gave the company a “buy” rating in a research note on Wednesday, November 4th. Morgan Stanley upped their price objective on shares of Amgen from $359.00 to $410.00 and gave the stock an “equal weight” rating in a research report on Wednesday, November 4th. Barclays increased their price objective on shares of Amgen from $380.00 to $400.00 and gave the company an “equal weight” rating in a report on Wednesday, October 21st. Bank of America boosted their target price on shares of Amgen from $312.00 to $317.00 and gave the stock an “underperform” rating in a research note on Wednesday, August 5th. Finally, Sanford C. Bernstein upped their price target on shares of Amgen from $345.00 to $400.00 and gave the stock a “market perform” rating in a research report on Wednesday, November 4th. One investment analyst has rated the stock with a Strong Buy rating, eleven have assigned a Buy rating, eighteen have issued a Hold rating and three have assigned a Sell rating to the company’s stock. According to MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus target price of $424.66.

Read Our Latest Analysis on AMGN

Amgen Price Performance

Shares of AMGN opened at $465.67 on Monday. The company has a debt-to-equity ratio of 3.60, a quick ratio of 1.20 and a current ratio of 1.48. Amgen Inc. has a one year low of $312.39 and a one year high of $483.99. The stock has a market capitalization of $251.89 billion, a price-to-earnings ratio of 27.01, a PEG ratio of 3.24 and a beta of 0.43. The stock has a 50 day moving average price of $425.31 and a 200 day moving average price of $381.17.

Amgen (NASDAQ:AMGN – Get Free Report) last posted its quarterly earnings data on Tuesday, November 3rd. The medical research company reported $6.45 EPS for the quarter, beating the consensus estimate of $5.79 by $0.66. The firm had revenue of $10.37 billion during the quarter, compared to the consensus estimate of $10.07 billion. Amgen had a return on equity of 114.99% and a net margin of 24.14%. The firm’s revenue was up 8.5% compared to the same quarter last year. During the same period in the prior year, the company earned $5.64 EPS. Equities research analysts forecast that Amgen Inc. will post 23.37 earnings per share for the current fiscal year.

Amgen Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Friday, December 11th. Stockholders of record on Friday, November 20th will be issued a dividend of $2.52 per share. The ex-dividend date of this dividend is Friday, November 20th. This represents a $10.08 dividend on an annualized basis and a dividend yield of 2.2%. Amgen’s dividend payout ratio is presently 58.47%.

About Amgen

(Free Report)

Amgen is a biotechnology company that discovers, develops, manufactures and commercializes medicines for serious illnesses. Its research and product portfolio span areas including cancer, cardiovascular disease, inflammation, bone health and rare diseases. The company’s medicines include Enbrel, Prolia, Xgeva and Repatha. Amgen serves patients and healthcare providers in the United States and markets its products internationally. Founded in 1980 and headquartered in Thousand Oaks, California, Amgen is led by Robert A. Bradway, who has served as its chief executive officer since 2012.

Featured Stories

Want to see what other hedge funds are holding AMGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amgen Inc. (NASDAQ:AMGN – Free Report).

Institutional Ownership by Quarter for Amgen (NASDAQ:AMGN)

Receive News & Ratings for Amgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen and related companies with MarketBeat.com's FREE daily email newsletter.